Reported Standalone quarterly numbers for Marksans Pharma are:
Net Sales at Rs 241.36 crore in December 2023 up 39.72% from Rs. 172.75 crore in December 2022.
Story continues below Advertisement
Quarterly Net Profit at Rs. 25.29 crore in December 2023 down 1.31% from Rs. 25.62 crore in December 2022.
EBITDA stands at Rs. 43.30 crore in December 2023 up 9.54% from Rs. 39.53 crore in December 2022.
Marksans Pharma EPS has decreased to Rs. 0.56 in December 2023 from Rs. 0.63 in December 2022.
Story continues below Advertisement
Marksans Pharma shares closed at 157.95 on February 13, 2024 (NSE) and has given 38.61% returns over the last 6 months and 138.96% over the last 12 months.
| Marksans Pharma | | Standalone Quarterly Results | in Rs. Cr. |
|
| Dec'23 | Sep'23 | Dec'22 | | Net Sales/Income from operations | 241.36 | 204.67 | 172.75 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 241.36 | 204.67 | 172.75 | | EXPENDITURE | | Consumption of Raw Materials | 117.16 | 102.83 | 82.88 | | Purchase of Traded Goods | 22.12 | 17.56 | 15.87 | | Increase/Decrease in Stocks | -1.46 | -5.90 | 1.10 | | Power & Fuel | -- | -- | -- | | Employees Cost | 20.47 | 18.23 | 13.80 | | Depreciation | 8.43 | 8.50 | 4.18 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 41.11 | 34.65 | 35.29 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 33.54 | 28.80 | 19.64 | | Other Income | 1.33 | 15.93 | 15.71 | | P/L Before Int., Excpt. Items & Tax | 34.87 | 44.73 | 35.35 | | Interest | 0.27 | 0.23 | 0.85 | | P/L Before Exceptional Items & Tax | 34.60 | 44.50 | 34.50 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | 34.60 | 44.50 | 34.50 | | Tax | 9.31 | 13.21 | 8.88 | | P/L After Tax from Ordinary Activities | 25.29 | 31.29 | 25.62 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 25.29 | 31.29 | 25.62 | | Equity Share Capital | 45.32 | 45.32 | 40.30 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 0.56 | 0.69 | 0.63 | | Diluted EPS | 0.56 | 0.69 | 0.63 | | EPS After Extra Ordinary | | Basic EPS | 0.56 | 0.69 | 0.63 | | Diluted EPS | 0.56 | 0.69 | 0.63 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
